Publication date: Jul 10, 2023
Immunohistochemistry-based protein biomarkers can provide useful prognostic information in cutaneous melanoma. The independent prognostic value of Ki-67 has been studied with variable results. PReferentially expressed Antigen in MElanoma (PRAME) immunohistochemistry is a useful new ancillary tool for distinguishing cutaneous nevi from melanoma; however, its prognostic value has not been well studied. We evaluated PRAME as a prognostic marker in cutaneous melanoma, compared to Ki-67. We analyzed the immunohistochemical expression of PRAME and Ki-67 in 165 melanocytic lesions, including 92 primary melanomas, 19 metastatic melanomas, and 54 melanocytic nevi using tissue microarrays. PRAME immunostaining was scored based on the percentage of positive nuclei: 0 75%. The percentage of Ki-67-positive tumor nuclei was used to calculate the proliferation index. PRAME and Ki-67 both showed significantly increased expression in melanomas compared to nevi (p
| Concepts | Keywords |
|---|---|
| Cutaneous | benign nevus |
| Immunohistochemistry | cutaneous malignant melanoma |
| Microarrays | Ki-67 |
| Tumor | PRAME |
| prognosis | |
| survival | |
| tissue microarray |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | nevi |
| disease | MESH | melanocytic nevi |
| disease | MESH | tumor |